Dissolution Testing For Bioequivalence
Dissolution Testing for Bioequivalence is a pharmaceutical analytical method that evaluates the rate and extent of drug release from a dosage form under standardized conditions to establish in vitro equivalence as a surrogate for in vivo bioequivalence in regulatory approval of generic drug products.
116
Publications
3.4K
Citations
503
Authors
174
Institutions
Publications per year
2017–2026
41
Parents
116
Dissolution Testing for Generic Drugs: An FDA Perspective
Om Anand, Lawrence X. Yu, Dale P. Conner et al. · The AAPS Journal · 2011 · 270 citations · Full text
1–5 of 116
503
Agencia Española de Medicamentos y Productos Sanitarios, Spain
9 publications · 281 citations
9
h-index
7
h-index
6
h-index
5
h-index
5
h-index
1–5 of 503
174
Center for Drug Evaluation and Research
Silver Spring, United States
8 h-index
16 publications
1.5K citations

Universitat de Miguel Hernández d'Elx
Elche, Spain
7 h-index
29 publications
731 citations
United States Food and Drug Administration
Silver Spring, United States
6 h-index
19 publications
1.6K citations
GlaxoSmithKline (United States)
Philadelphia, United States
4 h-index
5 publications
87 citations

Janssen (Belgium)
Beerse, Belgium
4 h-index
6 publications
100 citations
Universitat de València
Valencia, Spain
4 h-index
5 publications
123 citations
University of Michigan
Ann Arbor, United States
4 h-index
10 publications
342 citations
Agencia Española de Medicamentos y Productos Sanitarios
Madrid, Spain
4 h-index
4 publications
153 citations
1–8 of 174
16 publications · 564 citations
13
h-index
AAPSJ · 7 publications · 387 citations
8
h-index
6 publications · 110 citations
8
h-index
5 publications · 135 citations
6
h-index
Repository · 5 publications · 118 citations
5
h-index
1–5